Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 16, 2016 - Issue 1
Submit an article Journal homepage
955
Views
12
CrossRef citations to date
0
Altmetric
Drug Profiles

Cannabidiol as potential treatment in refractory pediatric epilepsy

Maria Chiara PaolinoChild Neurology, Headache Paediatric Center, Paediatric Sleep Disorders, NESMOS Department, Chair of Pediatrics, Faculty of Medicine and Psychology, Sapienza University, c/o Sant’Andrea Hospital, Rome, Italy
,
Alessandro FerrettiChild Neurology, Headache Paediatric Center, Paediatric Sleep Disorders, NESMOS Department, Chair of Pediatrics, Faculty of Medicine and Psychology, Sapienza University, c/o Sant’Andrea Hospital, Rome, Italy
,
Laura PapettiDepartment of Pediatrics, Child Neurology Division, Sapienza University of Rome, Rome, Italy
,
Maria Pia VillaChild Neurology, Headache Paediatric Center, Paediatric Sleep Disorders, NESMOS Department, Chair of Pediatrics, Faculty of Medicine and Psychology, Sapienza University, c/o Sant’Andrea Hospital, Rome, Italy
&
Pasquale ParisiChild Neurology, Headache Paediatric Center, Paediatric Sleep Disorders, NESMOS Department, Chair of Pediatrics, Faculty of Medicine and Psychology, Sapienza University, c/o Sant’Andrea Hospital, Rome, ItalyCorrespondence[email protected] [email protected]
Pages 17-21 | Published online: 09 Dec 2015
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

In recent years there has been great scientific and public interest focused on the therapeutic potential of compounds derived from cannabis for the treatment of refractory epilepsy in children. From in vitro and in vivo studies on animal models, cannabidiol (CBD) appears to be a promising anticonvulsant drug with a favorable side-effect profile. In humans, CBD efficacy and safety is not supported by well-designed trials and its use has been described by anecdotal reports. It will be necessary to investigate CBD safety, pharmacokinetics and interaction with other anti-epileptic drugs (AEDs) alongside performing double-blinded placebo-controlled trials in order to obtain conclusive data on its efficacy and safety in children.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 651.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.